- Home
- SAVA vs DMO Comparison
SAVA vs DMO Comparison
Compare SAVA & DMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- DMO
- Stock Information
- Founded
- SAVA 1998
- DMO 2009
- Country
- SAVA United States
- DMO United States
- Employees
- SAVA N/A
- DMO N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- DMO Trusts Except Educational Religious and Charitable
- Sector
- SAVA Health Care
- DMO Finance
- Exchange
- SAVA Nasdaq
- DMO Nasdaq
- Market Cap
- SAVA 157.5M
- DMO 136.8M
- IPO Year
- SAVA N/A
- DMO N/A
- Fundamental
- Price
- SAVA $2.82
- DMO $11.99
- Analyst Decision
- SAVA Buy
- DMO
- Analyst Count
- SAVA 2
- DMO 0
- Target Price
- SAVA $5.00
- DMO N/A
- AVG Volume (30 Days)
- SAVA 1.2M
- DMO 49.6K
- Earning Date
- SAVA 11-12-2025
- DMO 01-01-0001
- Dividend Yield
- SAVA N/A
- DMO 12.06%
- EPS Growth
- SAVA N/A
- DMO N/A
- EPS
- SAVA N/A
- DMO N/A
- Revenue
- SAVA N/A
- DMO N/A
- Revenue This Year
- SAVA N/A
- DMO N/A
- Revenue Next Year
- SAVA N/A
- DMO N/A
- P/E Ratio
- SAVA N/A
- DMO N/A
- Revenue Growth
- SAVA N/A
- DMO N/A
- 52 Week Low
- SAVA $1.15
- DMO $10.00
- 52 Week High
- SAVA $33.98
- DMO $11.80
- Technical
- Relative Strength Index (RSI)
- SAVA 38.79
- DMO 57.33
- Support Level
- SAVA $2.65
- DMO $11.85
- Resistance Level
- SAVA $3.30
- DMO $12.03
- Average True Range (ATR)
- SAVA 0.21
- DMO 0.10
- MACD
- SAVA -0.07
- DMO 0.00
- Stochastic Oscillator
- SAVA 18.02
- DMO 83.33
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About DMO Western Asset Mortgage Opportunity Fund Inc.
Western Asset Mortgage Defined Opportunity Fund Inc is a non-diversified, limited-term, closed-end management investment company. The fund's primary investment objective is to provide current income. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing in a diverse portfolio of mortgage-backed securities, consisting of non-agency residential mortgage-backed securities and commercial mortgage-backed securities.